

## Mirtazapine Disintegrating Formulation

Version 4.4      Revision Date: 01.10.2020      SDS Number: 50188-00016      Date of last issue: 23.03.2020  
Date of first issue: 23.01.2015

---

**SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Mirtazapine Disintegrating Formulation

**Manufacturer or supplier's details**

Company : Organon & Co.

Address : Rua Treze de Maio, 1161  
Campinas, São Paulo, Brazil B-2220

Telephone : 551-430-6000

Emergency telephone : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification in accordance with ABNT NBR 14725 Standard**

Acute toxicity (Oral) : Category 4

Reproductive toxicity : Category 2

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Nervous system)

Short-term (acute) aquatic hazard : Category 3

Long-term (chronic) aquatic hazard : Category 3

**GHS label elements in accordance with ABNT NBR 14725 Standard**

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H302 Harmful if swallowed.  
H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.  
H373 May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.  
H412 Harmful to aquatic life with long lasting effects.

---

## Mirtazapine Disintegrating Formulation

Version 4.4      Revision Date: 01.10.2020      SDS Number: 50188-00016      Date of last issue: 23.03.2020  
Date of first issue: 23.01.2015

Precautionary Statements : **Prevention:**  
 P201 Obtain special instructions before use.  
 P260 Do not breathe dust.  
 P270 Do not eat, drink or smoke when using this product.  
 P273 Avoid release to the environment.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**  
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.  
 Contact with dust can cause mechanical irritation or drying of the skin.  
 May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Classification	Concentration (% w/w)
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	Acute toxicity (Oral), Category 4 Reproductive toxicity, Category 2 Specific target organ toxicity - repeated exposure (Oral) (Nervous system), Category 2 Short-term (acute) aquatic hazard, Category 2 Long-term (chronic) aquatic hazard, Category 2	>= 20 -< 25
Citric acid	77-92-9	Eye irritation, Category 2A	>= 1 -< 5
Cellulose	9004-34-6		>= 1 -< 5
Magnesium stearate	557-04-0		>= 1 -< 5

**SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.

## Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.4	01.10.2020	50188-00016	Date of first issue: 23.01.2015

---

- |   |   |   |
|---|---|---|
| In case of skin contact                                     | : | Get medical attention.<br>In case of contact, immediately flush skin with soap and plenty of water.<br>Remove contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse.   |
| In case of eye contact                                      | : | If in eyes, rinse well with water.<br>Get medical attention if irritation develops and persists.  |
| If swallowed  | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.<br>Never give anything by mouth to an unconscious person.   |
| Most important symptoms and effects, both acute and delayed | : | Harmful if swallowed.<br>Suspected of damaging fertility. Suspected of damaging the unborn child.<br>May cause damage to organs through prolonged or repeated exposure if swallowed.<br>Contact with dust can cause mechanical irritation or drying of the skin.<br>Dust contact with the eyes can lead to mechanical irritation. |
| Protection of first-aiders                                  | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).   |
| Notes to physician  | : | Treat symptomatically and supportively.   |
- 

**SECTION 5. FIRE-FIGHTING MEASURES**

- |  |   |   |
|--|---|---|
| Suitable extinguishing media                   | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical  |
| Unsuitable extinguishing media                 | : | None known.   |
| Specific hazards during fire fighting          | : | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.<br>Exposure to combustion products may be a hazard to health.                   |
| Hazardous combustion products                  | : | Carbon oxides<br>Nitrogen oxides (NO <sub>x</sub> )<br>Metal oxides   |
| Specific extinguishing methods                 | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.<br>Use water spray to cool unopened containers.<br>Remove undamaged containers from fire area if it is safe to do so.<br>Evacuate area. |
| Special protective equipment for fire-fighters | : | In the event of fire, wear self-contained breathing apparatus.<br>Use personal protective equipment.  |
- 

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

- |                               |   |                                    |
|-------------------------------|---|------------------------------------|
| Personal precautions, protec- | : | Use personal protective equipment. |
|-------------------------------|---|------------------------------------|

## Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.4	01.10.2020	50188-00016	Date of first issue: 23.01.2015

---

- |   |   |  |
|---|---|--|
| tive equipment and emergency procedures               | : | Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).   |
| Environmental precautions                             | : | Avoid release to the environment.<br>Prevent further leakage or spillage if safe to do so.<br>Retain and dispose of contaminated wash water.<br>Local authorities should be advised if significant spillages cannot be contained.  |
| Methods and materials for containment and cleaning up | : | Sweep up or vacuum up spillage and collect in suitable container for disposal.<br>Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).<br>Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.<br>Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.<br>Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

---

**SECTION 7. HANDLING AND STORAGE**

- |                             |   |   |
|-----------------------------|---|---|
| Technical measures          | : | Static electricity may accumulate and ignite suspended dust causing an explosion.<br>Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.  |
| Local/Total ventilation     | : | Use only with adequate ventilation.   |
| Advice on safe handling     | : | Do not breathe dust.<br>Do not swallow.<br>Avoid contact with eyes.<br>Avoid prolonged or repeated contact with skin.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Minimize dust generation and accumulation.<br>Keep container closed when not in use.<br>Keep away from heat and sources of ignition.<br>Take precautionary measures against static discharges.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures            | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.<br>When using do not eat, drink or smoke.<br>Wash contaminated clothing before re-use.  |
| Conditions for safe storage | : | Keep in properly labeled containers.<br>Store locked up.<br>Store in accordance with the particular national regulations.   |
| Materials to avoid          | : | Do not store with the following product types:  |

## Mirtazapine Disintegrating Formulation

Version 4.4      Revision Date: 01.10.2020      SDS Number: 50188-00016      Date of last issue: 23.03.2020  
Date of first issue: 23.01.2015

Strong oxidizing agents

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8	TWA	25 µg/m <sup>3</sup>	Internal
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment: Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective

# SAFETY DATA SHEET



## Mirtazapine Disintegrating Formulation



Version 4.4      Revision Date: 01.10.2020      SDS Number: 50188-00016      Date of last issue: 23.03.2020  
Date of first issue: 23.01.2015

---

clothing (gloves, aprons, boots, etc).

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive

## Mirtazapine Disintegrating Formulation

Version 4.4      Revision Date: 01.10.2020      SDS Number: 50188-00016      Date of last issue: 23.03.2020  
Date of first issue: 23.01.2015

---

Oxidizing properties : The substance or mixture is not classified as oxidizing.  
Molecular weight : No data available  
Particle size : No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.  
Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Harmful if swallowed.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 1.588 mg/kg  
Method: Calculation method

**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Acute oral toxicity : LD50 (Rat): 320 - 490 mg/kg

**Citric acid:**

Acute oral toxicity : LD50 (Mouse): 5.400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l

## Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.4	01.10.2020	50188-00016	Date of first issue: 23.01.2015

---

Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

**Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg  
Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Citric acid:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Citric acid:**

Species : Rabbit  
Result : Irritation to eyes, reversing within 21 days  
Method : OECD Test Guideline 405

**Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.



## Mirtazapine Disintegrating Formulation

Version 4.4      Revision Date: 01.10.2020      SDS Number: 50188-00016      Date of last issue: 23.03.2020  
Date of first issue: 23.01.2015

---

**Components:****Magnesium stearate:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Test system: mammalian cells  
Result: negative

Test Type: sister chromatid exchange assay  
Test system: mammalian cells  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Rat  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

**Citric acid:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: in vitro micronucleus test  
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

## Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.4	01.10.2020	50188-00016	Date of first issue: 23.01.2015

---

**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Mouse  
Application Route : Oral  
Exposure time : 18 month(s)  
LOAEL : 200 mg/kg body weight  
Result : equivocal  
Target Organs : Liver

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
LOAEL : 20 mg/kg body weight  
Result : equivocal  
Target Organs : Liver, Thyroid

**Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

## Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.4	01.10.2020	50188-00016	Date of first issue: 23.01.2015

---

**Reproductive toxicity**

Suspected of damaging fertility. Suspected of damaging the unborn child.

**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Oral  
 Fertility: LOAEL: 15 mg/kg body weight  
 Symptoms: Effect on estrous cycle, Increase of early resorptions.  
 Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were detected.

Effects on fetal development : Test Type: Development  
 Species: Rat  
 Application Route: Oral  
 Developmental Toxicity: LOAEL: 100 mg/kg body weight  
 Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Development  
 Species: Rabbit  
 Application Route: Oral  
 Developmental Toxicity: NOAEL: 40 mg/kg body weight  
 Result: No adverse effects., No teratogenic effects.

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

**Citric acid:**

Effects on fetal development : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the

## Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.4	01.10.2020	50188-00016	Date of first issue: 23.01.2015

---

reproduction/developmental toxicity screening test  
 Species: Rat  
 Application Route: Ingestion  
 Method: OECD Test Guideline 422  
 Result: negative  
 Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative  
 Remarks: Based on data from similar materials

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

**Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Routes of exposure : Ingestion  
 Target Organs : Nervous system  
 Assessment : May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Species : Rat  
 LOAEL : 120 mg/kg  
 Application Route : Oral  
 Exposure time : 13 Weeks  
 Target Organs : Nervous system

Species : Dog  
 LOAEL : 15 mg/kg  
 Application Route : Oral  
 Exposure time : 52 Weeks  
 Target Organs : Nervous system  
 Symptoms : Tremors

Species : Dog  
 LOAEL : 20 mg/kg  
 Application Route : Oral  
 Exposure time : 13 Weeks  
 Target Organs : Nervous system, Testis  
 Symptoms : Tremors

**Citric acid:**

## Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.4	01.10.2020	50188-00016	Date of first issue: 23.01.2015

---

Species	:	Rat
NOAEL	:	4.000 mg/kg
LOAEL	:	8.000 mg/kg
Application Route	:	Ingestion
Exposure time	:	10 Days

**Cellulose:**

Species	:	Rat
NOAEL	:	>= 9.000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

**Magnesium stearate:**

Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Ingestion	:	Symptoms: Drowsiness, constipation, dry mouth, asthenia, Dizziness, Disorientation
-----------	---	--

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 6,92 mg/l Exposure time: 96 h Method: FDA 4.11
------------------	---	---

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 19,5 mg/l Exposure time: 48 h
---	---	---

Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 5,7 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
----------------------------------	---	--

	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 3,2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
--	---	--

## Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.4	01.10.2020	50188-00016	Date of first issue: 23.01.2015

---

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 3,6 mg/l  
Exposure time: 31 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0,32 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50 (Natural microorganism): > 1.000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC (Natural microorganism): < 100 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

**Citric acid:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1.535 mg/l  
Exposure time: 24 h

**Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Magnesium stearate:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

## Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.4	01.10.2020	50188-00016	Date of first issue: 23.01.2015

---

mg/l  
 Exposure time: 72 h  
 Test substance: Water Accommodated Fraction  
 Method: OECD Test Guideline 201  
 Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (*Pseudomonas putida*): > 100 mg/l  
 Exposure time: 16 h  
 Test substance: Water Accommodated Fraction  
 Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Citric acid:**

Biodegradability : Result: Readily biodegradable.  
 Biodegradation: 97 %  
 Exposure time: 28 d  
 Method: OECD Test Guideline 301B

**Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable.  
 Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Bioaccumulation : Species: *Oncorhynchus mykiss* (rainbow trout)  
 Bioconcentration factor (BCF): 334  
 Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 2,78

**Citric acid:**

Partition coefficient: n-octanol/water : log Pow: -1,72

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil****Components:****(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

Distribution among environ- : log Koc: 4,48

## Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.4	01.10.2020	50188-00016	Date of first issue: 23.01.2015

---

mental compartments

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues	:	Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****ANTT**

Not regulated as a dangerous good

---

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH)	:	Not applicable
--	---	----------------

Brazil. List of chemicals controlled by the Federal Police	:	Sodium hydrogencarbonate
--	---	--------------------------

**International Regulations****The ingredients of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined



# SAFETY DATA SHEET



## Mirtazapine Disintegrating Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.4	01.10.2020	50188-00016	Date of first issue: 23.01.2015

---

### SECTION 16. OTHER INFORMATION

#### Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

# SAFETY DATA SHEET



## Mirtazapine Disintegrating Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
4.4	01.10.2020	50188-00016	Date of first issue: 23.01.2015

---

BR / Z8